Latest news and press releases about RxSight, Inc. (RXST): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets.
Price
| Price | $5.40 |
| Market Cap | $224M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.86 |
| EV / EBITDA | -5.69 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -17.35% |
| Return on Invested Capital | -20.12% |
| Return on Assets | -13.31% |
| Gross Margin | 77.50% |
| Operating Margin | -43.20% |
| Net Margin | -36.80% |
Related companies: BFLY · CERS · DCTH · DMAC · KIDS · NPCE · SMLR
Explore sector: Healthcare · Medical - Devices
More sections of RXST: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks